{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:25:38Z","timestamp":1781857538721,"version":"3.54.5"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.crd.0000233757.15181.67","type":"journal-article","created":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T23:04:17Z","timestamp":1160780657000},"page":"286-291","source":"Crossref","is-referenced-by-count":81,"title":["The Metabolic Syndrome in Women"],"prefix":"10.1097","volume":"14","author":[{"given":"J Gabriel","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","article-title":"Deaths: Leading Causes for 2002. National Vital Statistics Reports; vol 53 no 17.","author":"Anderson","year":"2005"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000080884.27358.49","article-title":"Relationship of metabolic syndrome and fibrinolytic dysfunction in cardiovascular disease.","volume":"108","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events.","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988: role of insulin resistance in human disease.","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement.","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal.","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/diacare.27.11.2676","article-title":"Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and\/or cardiovascular disease.","volume":"27","author":"Stern","year":"2004","journal-title":"Diabetes Care"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/diacare.28.2.385","article-title":"The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.","volume":"28","author":"McNeill","year":"2005","journal-title":"Diabetes Care"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1001\/archinte.165.22.2644","article-title":"Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.","volume":"165","author":"Wannamethee","year":"2005","journal-title":"Arch Intern Med"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.104.516948","article-title":"Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study.","volume":"112","author":"Dekker","year":"2005","journal-title":"Circulation"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/154099904322966146","article-title":"High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction.","volume":"13","author":"Amowitz","year":"2004","journal-title":"J Womens Health"},{"issue":"suppl 1","key":"R14-5-20210203","first-page":"177","article-title":"Coronary artery disease: is menopause a risk factor?","volume":"95","author":"Gohlke-Barwolf","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0140-6736(88)91612-1","article-title":"Polycystic ovaries: a common finding in normal women.","volume":"1","author":"Polson","year":"1988","journal-title":"Lancet"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-126-1-199701010-00005","article-title":"Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.","volume":"126","author":"Birdsall","year":"1997","journal-title":"Ann Intern Med"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","article-title":"Mortality of women with polycystic ovary syndrome at long-term follow-up.","volume":"51","author":"Pierpoint","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.0000020681.19400.8A","article-title":"Impaired carotid viscoelastic properties in women with polycystic ovaries.","volume":"106","author":"Lakhani","year":"2002","journal-title":"Circulation"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/01.CIR.103.10.1410","article-title":"Polycystic ovary syndrome is associated with endothelial dysfunction.","volume":"103","author":"Paradisi","year":"2001","journal-title":"Circulation"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1210\/jc.2001-012034","article-title":"Difference in adipose tissue metabolism between postmenopausal and perimenopausal women.","volume":"87","author":"Ferrara","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-5-20210203","first-page":"2446","article-title":"Subcutaneous adipose tissue metabolism at menopause: importance of body fatness and regional fat distribution.","volume":"85","author":"Mauriege","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-5-20210203","first-page":"339","article-title":"La differenciation sexuelle, facteur determinant des formes de l'obesite.","volume":"30","author":"Vague","year":"1947","journal-title":"Presse Med"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1172\/JCI111040","article-title":"Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution.","volume":"72","author":"Krotkiewski","year":"1983","journal-title":"J Clin Invest"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-123-9-199511010-00005","article-title":"Changes in energy balance and body composition at menopause: a controlled longitudinal study.","volume":"123","author":"Poehlman","year":"1995","journal-title":"Ann Intern Med"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.CIR.0000115514.44135.A8","article-title":"Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women.","volume":"109","author":"Kip","year":"2004","journal-title":"Circulation"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.104.503805","article-title":"Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome.","volume":"112","author":"LaMonte","year":"2005","journal-title":"Circulation"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00042192-200211000-00012","article-title":"Comparison of VO2 max and disease risk factors between perimenopausal and postmenopausal women.","volume":"9","author":"Lynch","year":"2002","journal-title":"Menopause"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00041433-199806000-00005","article-title":"The role of hepatic lipase in lipoprotein metabolism and atherosclerosis.","volume":"9","author":"Santamarina-Fojo","year":"1998","journal-title":"Curr Opin Lipidol"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/diacare.24.5.902","article-title":"Deterioration of the metabolic risk profile in women.","volume":"24","author":"Pascot","year":"2001","journal-title":"Diabetes Care"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0378-5122(90)90012-U","article-title":"Influence of menopause on serum lipids and lipoproteins.","volume":"12","author":"Jensen","year":"1990","journal-title":"Maturitas"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/jcem-67-1-30","article-title":"Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women.","volume":"67","author":"Campos","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2362.1997.1160662.x","article-title":"Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study.","volume":"27","author":"Poehlman","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.87.4.1135","article-title":"Effects of age, sex and menopausal status on plasma lipoprotein (a) levels. The Framingham Offspring Study.","volume":"87","author":"Jenner","year":"1993","journal-title":"Circulation"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.105.567107","article-title":"Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.","volume":"113","author":"Kathiresan","year":"2006","journal-title":"Circulation"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2005.02.051","article-title":"Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha and fibrinogen to abdominal adipose tissue blood pressure and cholesterol and triglyceride levels in healthy postmenopausal women.","volume":"96","author":"Piche","year":"2005","journal-title":"Am J Cardiol"},{"key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/1520-7560(200005\/06)16:3<192::AID-DMRR114>3.0.CO;2-G","article-title":"Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.","volume":"16","author":"Bastard","year":"2000","journal-title":"Diabetes Metab Res Rev"},{"key":"R39-5-20210203","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","article-title":"High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.","volume":"98","author":"Thogersen","year":"1998","journal-title":"Circulation"},{"key":"R40-5-20210203","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1161\/01.CIR.95.12.2623","article-title":"Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.","volume":"95","author":"van der Bom","year":"1997","journal-title":"Circulation"},{"key":"R41-5-20210203","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0026-0495(90)90164-8","article-title":"Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.","volume":"39","author":"Landin","year":"1990","journal-title":"Metabolism"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0378-5122(93)90119-3","article-title":"Passage of the menopause is followed by haemostatic changes.","volume":"17","author":"Lindoff","year":"1993","journal-title":"Maturitas"},{"key":"R43-5-20210203","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized controlled trials.","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R44-5-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ije\/dyi281","article-title":"Weight change and changes in the metabolic syndrome as the French population moves toward overweight: the DESIR Cohort.","volume":"35","author":"Hillier","year":"2006","journal-title":"Int J Epidemiol"},{"key":"R45-5-20210203","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"R46-5-20210203","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial IN macroVasclar Events): a randomized controlled trial.","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"R47-5-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.CIR.0000153272.48711.B9","article-title":"Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome.","volume":"111","author":"Sola","year":"2005","journal-title":"Circulation"},{"key":"R48-5-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein.","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"R49-5-20210203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation\/CRP Evaluation (PRINCE): a randomized trial and cohort study.","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"R50-5-20210203","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER Trial.","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045415-200611000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T04:29:21Z","timestamp":1618028961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200611000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000233757.15181.67","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}